News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on ImpediMed.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: ImpediMed pops over 60pc after BIS technology named in new US guidelines
News
Top 10 at 10: Cancer fighters, new lithium leaders, and a lucrative takeover offer
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but keep watchful eye on upcoming catalysts
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise, Mach 7 lands largest contract and posts record quarter
Health & Biotech
ASX Health Stocks: Sonic snaps up stake in Microba, sending MAP share price 60pc higher
Health & Biotech
ASX Health Stocks: Pot stock BOD’s Phase 1 results; Paradigm and Impedimed shake up exec teams
Health & Biotech
Check Up: The TGA is 100pc cool with the world’s first faecal transplant, oral delivery being studied
Experts
ScoPo’s Powerplays: Stress eases as ASX health stocks enjoy much needed rally
Health & Biotech
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations
Health & Biotech
ScoPo’s Powerplays: Is it time to fill the Christmas stocking early with some ASX health stocks?
Experts
ScoPo’s Powerplays: Calmer week for ASX health stocks with some alarming stats about how many people drink instant coffee
Health & Biotech
ASX Health Stocks: Paradigm soars 19pc after meeting primary endpoint of Phase 2 trial
News
Market highlights and 5 ASX small caps to watch on Monday
Experts
ScoPo’s Powerplays: ASX health stocks offer bargains galore during tax time sell down
Experts
ScoPo’s Powerplays: Health stocks on a wave of jitters as inflation storm gathers
Health & Biotech
ASX Health Stocks: ImpediMed extends SOZO contract with global pharma AstraZeneca
Health & Biotech